Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome

Piero Ruggenenti, Barbara Ruggiero, Paolo Cravedi, Marina Vivarelli, Laura Massella, Maddalena Marasà, Antonietta Chianca, Nadia Rubis, Bogdan Ene-Iordache, Michael Rudnicki, Rosa Maria Pollastro, Giovambattista Capasso, Antonio Pisani, Marco Pennesi, Francesco Emma, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review


The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change disease (MCD), mesangial proliferative GN (MesGN), or FSGS may be poor and with major treatment toxicity. This academic,multicenter, off-on trial (ClinicalTrials.gov #NCT00981838) primarily evaluated the effects of rituximab therapy followed by immunosuppression withdrawal on disease recurrence in 10 children and 20 adults with MCD/MesGN (n=22) or FSGS who had suffered ≥2 recurrences over the previous year and were in steroidinduced remission for ≥1 month. Participants received one dose (n=28) or two doses of rituximab (375 mg/m2 intravenously).At 1 year, allpatientswere in remission: 18were treatment-free and 15 never relapsed.Compared with the year before rituximab treatment, total relapses decreased from 88 to 22 and the per-patient median number of relapses decreased from 2.5 (interquartile range [IQR], 2-4) to 0.5 (IQR, 0-1; P2 (P=0.01),with the largest increases in children and in FSGS subgroups. The mean height z score slope stabilized in children (P

Original languageEnglish
Pages (from-to)850-863
Number of pages14
JournalJournal of the American Society of Nephrology
Issue number4
Publication statusPublished - Apr 1 2014

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)


Dive into the research topics of 'Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome'. Together they form a unique fingerprint.

Cite this